| 4.74 0.35 (7.97%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.86 |
1-year : | 6.84 |
| Resists | First : | 5.01 |
Second : | 5.86 |
| Pivot price | 4.55  |
|||
| Supports | First : | 4.5 |
Second : | 4.19 |
| MAs | MA(5) : | 4.53 |
MA(20) : | 4.62 |
| MA(100) : | 4.91 |
MA(250) : | 6.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.1 |
D(3) : | 29 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 8.97 | Low : | 3.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LFCR ] has closed below upper band by 9.6%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.81 - 4.83 | 4.83 - 4.86 |
| Low: | 4.39 - 4.43 | 4.43 - 4.46 |
| Close: | 4.69 - 4.74 | 4.74 - 4.79 |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Wed, 02 Sep 2026
Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative
Wed, 02 Sep 2026
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
Sun, 23 Aug 2026
LFCR | Lifecore Biomedical, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative
Wed, 12 Aug 2026
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wed, 05 Aug 2026
Lifecore Signs Six New Programs, Including Two Commercial-Stage - Stock Titan
Wed, 15 Jul 2026
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 38 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 77.3 (%) |
| Shares Short | 2,610 (K) |
| Shares Short P.Month | 2,380 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.9 |
| Profit Margin | -23.8 % |
| Operating Margin | 7.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 3.42 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.77 |
| PEG Ratio | 2.6 |
| Price to Book value | -5.27 |
| Price to Sales | 1.38 |
| Price to Cash Flow | 14.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|